CYTOSORBENTS CORPORATION Long-Term Debt, Maturity, Year Two
CYTOSORBENTS CORPORATION (CTSO) had Long-Term Debt, Maturity, Year Two of $18.40 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Maturity, Year Two and Three
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo · last filed 2026-08-06
- 2026-06-30: Long-Term Debt, Maturity, Year Two $18.40M.
- 2026-03-31: Long-Term Debt, Maturity, Year Two $18.40M.
- 2024-09-30: Long-Term Debt, Maturity, Year Two $2.50M.
- 2024-03-31: Long-Term Debt, Maturity, Year Two $1.88M.
| Period end | Long-Term Debt, Maturity, Year Two | Long-Term Debt, Maturity, Year Two as first filed |
|---|---|---|
| 2026-06-30 | $18.40M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $18.40M 10-Q · filed 2026-05-13 | |
| 2024-09-30 | $2.50M 10-Q · filed 2024-11-07 | |
| 2024-03-31 | $1.88M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $2.50M 10-K · filed 2024-03-15 | |
| 2023-09-30 | $3.33M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $3.33M 10-Q · filed 2023-08-01 | |
| 2023-03-31 | $2.50M 10-Q · filed 2023-05-02 | |
| 2022-12-31 | $2.50M 10-K · filed 2023-03-09 | |
| 2020-03-31 | $8.33M 10-Q · filed 2020-08-04 | $10.00M 10-Q · filed 2020-05-05 |
| 2019-12-31 | $10.00M 10-K · filed 2020-03-05 | |
| 2019-09-30 | $7.50M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $1.25M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $1.67M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $666.67K 10-K · filed 2019-03-07 | |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $4.00M 10-K · filed 2018-03-08 | |
| 2017-09-30 | $3.00M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $2.00M 10-Q · filed 2017-08-07 | |
| 2017-03-31 | $1.67M 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $1.67M 10-K · filed 2017-03-03 | |
| 2016-09-30 | $1.67M 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $1.67M 10-Q · filed 2016-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |